Consent given pursuant to sections 14 and 14A for the importation and supply of the therapeutic goods specified - Apotex Pty Ltd

Overview

The Therapeutic Goods Act 1989, enacted by the Parliament of Australia, was introduced to ensure the safety, quality, and efficacy of therapeutic goods, including medicines, medical devices, and blood products. The Act provides a framework for regulating these goods, aiming to protect public health and safety. In 2014, under sections 14 and 14A of the Act, the delegate of the Secretary of the Department of Health granted Apotex Pty Ltd consent to import and supply specific batches of indapamide hemihydrate modified release tablets, despite the products not fully complying with the labelling requirements outlined in Therapeutic Goods Order No. 69. This consent was granted to address an immediate supply issue, ensuring continued availability of the medication while mitigating potential risks through specific conditions, such as the distribution of a ‘Dear Pharmacist’ letter to advise on the labelling discrepancy.

Scope and Application

The Therapeutic Goods Act 1989 applies to the regulation of therapeutic goods in Australia, covering a wide range of products including medicines, medical devices, blood, tissues, and therapeutic goods advertised to the public. The Act applies to manufacturers, importers, suppliers, and sponsors of therapeutic goods, ensuring that these products meet safety, quality, and efficacy standards. The Act's jurisdiction extends across the Commonwealth of Australia, and its regulations apply uniformly throughout the states and territories. Certain products and activities may be subject to exclusions or exemptions, often specified in subordinate instruments or specific orders. For instance, under Section 14 and 14A of the Act, consent can be granted for the supply of goods that do not fully comply with certain regulatory requirements, subject to specific conditions. This particular consent granted to Apotex Pty Ltd for the importation and supply of indapamide hemihydrate modified release tablets allows for an exception to the usual labelling requirements, specifically concerning the format of batch and expiry numbers. The consent is in effect until the specified batches are exhausted, and it includes a condition that a 'Dear Pharmacist' letter must accompany each batch to inform pharmacists and, by extension, patients about the labelling discrepancy.

Key Provisions

The Therapeutic Goods Act 1989, in particular sections 14 and 14A, provide a framework for the regulation of therapeutic goods in Australia. Section 14 of the Act allows the Secretary of the Department of Health to consent to the importation and supply of therapeutic goods that do not comply with specific regulatory requirements. In the case of Apotex Pty Ltd’s application, the delegate of the Secretary has granted consent for the importation and supply of indapamide hemihydrate tablets, which do not conform to the labelling requirements stipulated in the Therapeutic Goods Order No. 69. Specifically, the consent allows for the importation of the aforementioned products, which lack the appropriate prefixes before the batch and expiry numbers on their labels. The consent granted under the Act imposes certain obligations on the parties involved. Apotex Pty Ltd must ensure that a ‘Dear Pharmacist’ letter is included with each batch of the affected products. This letter serves to inform pharmacists to remind patients to retain the blister packs with the correctly labelled carton. This condition aims to mitigate any potential risks associated with the non-conformance of the product labels. Under the Therapeutic Goods Act 1989, breaches of the conditions set forth in consents such as this one can have significant consequences. Although specific penalties are not outlined in the notice, generally, the Act allows for enforcement actions that could include fines and other penalties for non-compliance. The Therapeutic Goods Regulations 1990 further detail the possible sanctions, which can range from civil penalties for corporations to criminal penalties for individuals, depending on the severity and intent behind the breach. These measures are designed to uphold the quality, safety, and efficacy of therapeutic goods available in Australia.